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Background Sub-Saharan Africa (SSA) has the highest burden of HIV in the
world and a rising prevalence of cardiometabolic disease; however,
the interrelationship between HIV, antiretroviral therapy (ART) and
cardiometabolic traits is not well described in SSA populations.
Methods We conducted a systematic review and meta-analysis through
MEDLINE and EMBASE (up to January 2012), as well as direct
author contact. Eligible studies provided summary or individual-
level data on one or more of the following traits in HIVþ and
HIV-, or ARTþ and ART- subgroups in SSA: body mass index
(BMI), systolic blood pressure (SBP), diastolic blood pressure
(DBP), high-density lipoprotein (HDL), low-density lipoprotein
(LDL), triglycerides (TGs) and fasting blood glucose (FBG) or gly-
cated hemoglobin (HbA1c). Information was synthesized under a
random-effects model and the primary outcomes were the standar-
dized mean differences (SMD) of the specified traits between sub-
groups of participants.
Results Data were obtained from 49 published and 3 unpublished studies
which reported on 29 755 individuals. HIV infection was associated
with higher TGs [SMD, 0.26; 95% confidence interval (CI), 0.08 to
0.44] and lower HDL (SMD, 0.59; 95% CI, 0.86 to 0.31), BMI
(SMD, 0.32; 95% CI, 0.45 to 0.18), SBP (SMD, 0.40; 95% CI,
0.55 to 0.25) and DBP (SMD, 0.34; 95% CI, 0.51 to 0.17).
Among HIVþ individuals, ART use was associated with higher LDL
(SMD, 0.43; 95% CI, 0.14 to 0.72) and HDL (SMD, 0.39; 95% CI,
0.11 to 0.66), and lower HbA1c (SMD, 0.34; 95% CI, 0.62 to
0.06). Fully adjusted estimates from analyses of individual par-
ticipant data were consistent with meta-analysis of summary esti-
mates for most traits.
Conclusions Broadly consistent with results from populations of European des-
cent, these results suggest differences in cardiometabolic traits be-
tween HIV-infected and uninfected individuals in SSA, which
might be modified by ART use. In a region with the highest
burden of HIV, it will be important to clarify these findings to
reliably assess the need for monitoring and managing cardiometa-
bolic risk in HIV-infected populations in SSA.
Keywords HIV, ART, cardiometabolic disease, sub-Saharan Africa
Introduction
Sub-Saharan Africa (SSA) has the highest burden of
HIV in the world, with approximately 22.9 million
prevalent cases and 1.9 million new infections re-
corded in 2010.1 The estimated 1.3 million people
who died of HIV-related illnesses in SSA in 2009 com-
prised 72% of the global mortality attributable to the
epidemic.2 Anti-retroviral therapy (ART) coverage in
this region has rapidly increased over the past decade,
with 49% of eligible cases receiving treatment in
2010.1 Expanding use of ART has led to a notable
decline in HIV-associated morbidity and death in
SSA.3 As life expectancy among HIV-infected people
improves, it is crucial to understand the long-term
impact of HIV and its treatment in this region.4
Parallel to the changing landscape of HIV care,
the burden of cardiometabolic diseases in SSA is
increasing,5 with expected deaths attributable to car-
diovascular disease projected to double to 2.4 million
in 2030 relative to reports from 2000.6 These data
suggest that cardiometabolic diseases will become a
major health problem in SSA, competing with infec-
tious diseases for limited health resources.7–9
Several studies in populations of European descent
suggest that HIV infection and ART are independently
associated with an increased risk of cardiometabolic
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disease, including cardiovascular disease, dyslipidae-
mia and type 2 diabetes (T2D).10–13 However, findings
appear to be inconsistent even within these studies,
and the true direction and magnitude of these asso-
ciations remain uncertain. A large prospective study
reported a 26% relative increase in the rate of myo-
cardial infarction (MI) per year of ART exposure
during the first 4–6 years of use.14 In 2003, to address
possibly increased cardiometabolic risk in this group,
the HIV Medicine Association of the Infectious
Disease Society of America and the Adult AIDS
Clinical Trials Group published guidelines specifically
for management of dyslipidaemia in HIV-infected in-
dividuals.15 However, these guidelines were primarily
based on evidence from European studies and have
not been widely implemented in SSA.16
Importantly, there is some evidence to suggest that
there may be differences in cardiometabolic risk pro-
files in people of African descent compared with
people of European descent,17–20 implying that the
aetiology of cardiometabolic disease, and the distribu-
tion and spectrum of risk factors, might differ in
African populations. Examples include the differential
tobacco usage patterns in SSA compared with other
regions, as well as differences in alcohol consumption
patterns in populations of African descent. Further-
more, it has been reported that the predominant
virus strains responsible for HIV infection in SSA
are HIV-1, group M (major) subtypes A and C,21
which differ as much as 30% in their genomes from
HIV-1 subtype B, responsible for the infections in
North America and Europe.21,22 The clinical conse-
quences of these subtype differences are, as yet, un-
clear. Additionally, there is precedent for differences
in the efficacy of infectious disease treatments in in-
dividuals of African descent, such as that seen in
interferon treatment for chronic hepatitis C.23 These
potential differences in HIV and ART associations
with cardiometabolic traits, if any, have not been re-
liably clarified.
In this context, it is important to examine possible
associations between HIV infection, ART treatment
and cardiometabolic traits in SSA. Assessing these as-
sociations will help inform and guide future research
and public health responses in the region. We there-
fore conducted a systematic review and meta-analysis
of published and unpublished data to assess these
associations in SSA.
Methods
Search strategy and identification of studies
This systematic review was conducted and reported in
accordance with the PRISMA guidelines. This study
focused on differences in cardiometabolic traits be-
tween HIV-infected and uninfected individuals, and
between those receiving and not receiving treatment.
A group of eight commonly accepted cardiometabolic
traits were selected a priori for inclusion in this ana-
lysis: body mass index (BMI), systolic blood pressure
(SBP), diastolic blood pressure (DBP), serum high-
density lipoprotein cholesterol (HDL), serum low-dens-
ity lipoprotein cholesterol (LDL), triglycerides (TGs),
fasting blood glucose(FBG) and glycated haemoglobin
(HbA1c). We did not examine lipodystrophy as a risk
factor due to the marked variability in assessment cri-
teria in the literature. Using a structured search strat-
egy (Supplementary Figures 1–2, available as
Supplementary data at IJE online), PUBMED and
EMBASE databases were queried for articles written
in English before the 1 January 2012. Published ab-
stracts were reviewed and assessed for inclusion in the
study. Those meeting the following inclusion criteria
were listed for full text review (Box 1): described
data on the relevant cardiometabolic traits in compar-
able HIVþ and HIV- populations, or comparable ARTþ
and ART naive groups; and included adult (aged 18
years or over) Black participants based in SSA, as
defined by the WHO African region.24 Comparability
between groups was defined as data collection using
similar study procedures for both individuals infected
and those uninfected with HIV, or ART users and
nonusers. Two reviewers (D.G.D. and J.R.) independ-
ently assessed studies for eligibility. Consensus for eli-
gibility between the two reviewers was 495%. Any
discrepancies in eligible studies listed were resolved
by consensus discussion. Studies not meeting both eli-
gibility criteria were not included in the final review.
We excluded case reports with fewer than five partici-
pants. Electronic searches were supplemented by cross-
Box 1 Eligibility criteria for inclusion in the systematic review
Inclusion criteria
Population  A population or cohort consisting of adult Black participants based in sub-Saharan Africa,
as defined by the World Health Organization African region
 Consists of comparable HIVþ and HIV populations or comparable ARTþ and ART naive groups
Outcome  Presents data on at least one of the following: body mass index, systolic blood pressure,
diastolic blood pressure, serum high-density lipoprotein cholesterol, low-density lipoprotein
cholesterol and triglycerides, fasting blood glucose or HbA1c
ART, antiretroviral therapy.
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referencing of cited reference lists from retrieved art-
icles and reviews.
Following full text review of all potentially eligible
articles, those identified as fulfilling the inclusion cri-
teria (Figure 1) were collated for analysis. We con-
tacted the corresponding authors of all eligible
articles, inviting their participation in this study. We
worked with these authors to confirm the accuracy of
extracted published data and to obtain additional rele-
vant unpublished data for this review. Responses were
received from 69.7% of the contacted authors, of
whom 68.4% agreed to collaborate on this meta-ana-
lysis. We received data from 85.0% of collaborating
groups. All studies were reviewed and approved by
their respective research ethics committees. Full details
of the search strategy, all identified articles and rea-
sons for exclusion if applicable can be found in
Supplementary Figures 1–2 and Supplementary Table
1, available as Supplementary data at IJE online.
Data abstraction and synthesis
Year, country, publication status (published/unpub-
lished) and study type (cohort/case-control) were re-
corded for each study. The following data were
extracted for relevant subgroups (HIVþ, HIV,
ARTþ, ART) within each study: number of individ-
uals, mean age, sex distribution, means and SDs for
pre-specified cardiometabolic traits, and fasting status
at time of measurement (Supplementary Table 2,
available as Supplementary data at IJE online).
HIV status was defined by classification in each in-
dividual study without alteration. HIV infection was
considered irrespective of ART status, and individuals
receiving ART were not excluded from this group. We
defined ‘ART use’ as receipt of ART medication at the
time of cardiometabolic trait measurement in the ori-
ginal report. Due to heterogeneous study designs and
the frequent lack of specific ART-related data in non-
ART-centric studies, no specific data were gathered on
Figure 1 Study selection
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ART type, ART duration pre-measurement or calendar
period during receipt of ART. In accordance with the
International System of Units (SI), all cardiometabolic
measurements were converted to mmol/l, %, mmHg
or kg/m2, as appropriate.
Individual-level participant data from the
General Population Cohort Study
In order to explore the impact of residual confound-
ing on our estimates, and to assess consistency be-
tween unadjusted estimates from summary-level
data and fully adjusted estimates from individual-
level data, we also analysed previously unpublished
individual-level data from one of the studies included
in the meta-analysis—the General Population Cohort
(GPC) study. These individual-level analyses were
performed on 5586 participants, comprising 18.8% of
the total number of participants included in this
meta-analysis.
The GPC study is a population-based cohort study of
approximately 22 000 individuals living in rural south-
west Uganda. This cohort was established in 1989 by
the Medical Research Council Programme on AIDS in
Uganda to assess trends in the prevalence and inci-
dence of HIV infection in the population. Since then,
an annual census is taken of the entire population to
collect basic demographic information. From this
census, consenting individuals are invited to take
part in an interviewer-mediated questionnaire, to
have their biophysical measurements taken and to
have blood samples drawn for analysis. GPC partici-
pants found to be HIV-infected are invited to join the
Rural Clinical Cohort for further follow-up. The Rural
Clinical Cohort encompasses all consenting HIVþ par-
ticipants within the GPC and gathers data on their
health and disease progression, in addition to provid-
ing care and access to ART. Full details of the cohort
structure, measurement techniques and the annual
HIV survey have been published elsewhere.25,26
In the GPC, detailed individual-level data were col-
lected on HIV status, ART, age, sex, BMI, lipid factors,
blood pressure, HbA1c levels, education status, smok-
ing and household-level clustering (Supplementary
Table 3, available as Supplementary data at IJE
online). This study was approved by the Science and
Ethics Committee of the Uganda Virus Research
Institute, the Uganda National Council for Science
and Technology and the East of England-Cambridge
South (formerly Cambridgeshire 4) NHS Research
Ethics Committee UK.
Statistical analysis
Because we anticipated heterogeneity among results
of studies due to potential differences in underlying
genetic susceptibility, health care infrastructure and
monitoring of chronic disease among individuals
with and without HIV and those using ART, we
used random-effects meta-analyses in our primary
analyses. However, as results from random-effects
meta-analyses may not always be conservative, we
also compared random and fixed-effects estimates.
We examined standardized mean difference (SMD)27
between relevant groups (HIVþ, HIV, ARTþ, ART)
as the primary measure of association for each trait
for ease of interpretation. This summary measure
allows the reader to compare differences in disparate
cardiometabolic traits on a single scale, and compre-
hend these differences without an underlying know-
ledge of the normal values and distribution of the
traits in question. The I2 statistic was used to assess
heterogeneity between studies.28
We initially explored potential sources of heterogen-
eity through the visual inspection of forest and
Galbraith plots. Meta-regression and stratified ana-
lysis approaches were then used to assess the contri-
bution of study-level variables to heterogeneity in
summary estimates. Variables assessed were: study
type (cohort/case-control), study size, date of publica-
tion, study location, publication status (published/un-
published), mean participant BMI, mean participant
age, sex distribution, mean difference in BMI between
groups, mean age difference between groups, and pro-
portion of HIV-infected individuals on ART in each
study (for comparisons between HIV-infected and un-
infected individuals). For evaluation of heterogeneity
by study location, studies were initially grouped ac-
cording to UN geographical sub-areas as follows: East
Africa, Central Africa, West Africa and Southern
Africa. However, as data gathered from West and
Central African regions were limited, these were col-
lapsed for further analysis. Factors were identified as
contributing to between-study heterogeneity, when a
substantial reduction in heterogeneity was observed
on adjustment for the factor in meta-regression.
Heterogeneity resulting from differing ART drug
class could not be explored because of the small
number of studies that reported this information.
Furthermore, we could not explore heterogeneity by
participant fasting status, as a large proportion of stu-
dies did not report status during blood draw for lipid
traits and all studies reporting glucose measurements
were on fasted individuals. We also sought to system-
atically explore the potential impact of outliers on es-
timates from meta-analysis for each by evaluating the
stability of meta-analysed SMD estimates to sequen-
tial exclusion of single studies.
In order to assess consistency between estimates
from adjusted individual-level data and unadjusted
summary data, we carried out individual participant
data analysis on a subset of the meta-analytical data
using the GPC study. We calculated SMD estimates
for the differences in cardiometabolic traits associated
with HIV infection and ART use, adjusted for age, sex,
BMI, education level, smoking status and ART use
(among HIV-infected individuals), using linear
mixed-effects models, including random effects for
data clustering at household and village levels. Age
and BMI were added as continuous variables whereas
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sex, education level, smoking status and ART use
were all added as categorical variables. All analyses
were conducted in Stata version 11.0.
Results
We analysed 5229–77 datasets from 14 countries
(Figure 2), providing study-level data on 29 755 par-
ticipants (23 119 from previously published studies
and 6636 participants from unpublished studies;
Unpublished data acquired from personal communi-
cations with C. Fourie, A. Schutte, and the MRC/
UVRI; Table 1). Studies were broadly distributed
across the three regions in SSA, with more partici-
pants from East Africa than Southern Africa or
West & Central Africa (Table 1). Of these 52 studies,
nine were conducted among HIV and tuberculosis co-
infected patients, two among malnourished popula-
tions and two among pregnant women. None of
these study-level factors explained an appreciable por-
tion of between study heterogeneity in meta-regres-
sion analyses (Table 2).
HIV and cardiometabolic traits
In this meta-analysis of summary data from up to
29 755 study participants, we found that HIV infection
was associated with lower mean BMI (SMD, 0.32;
95% CI, 0.45 to 0.18) (Figure 3). For blood lipids,
HIV infection was associated with higher mean TG
levels (SMD, 0.26; 95% CI, 0.08 to 0.44) and lower
mean HDL levels (SMD, 0.59; 95% CI, 0.86 to
0.31), whereas no marked difference in mean LDL
was observed between HIV infected and uninfected
individuals (SMD, 0.16; 95% CI, 0.34 to 0.03). HIV
infection was also associated with lower DBP (SMD,
0.34; 95% CI, 0.51 to 0.17) and SBP (SMD,
0.40; 95% CI, 0.55 to 0.25) (Figure 3). Based
on summary data from up to 6064 study participants,
we did not find any evidence of association between
HIV infection and fasting blood glucose or HbA1c
(Figure 3). Study-level and combined summary esti-
mates for each trait are illustrated in Supplementary
Figures 3–10, available as Supplementary data at IJE
online. Comparison of combined SMD estimates from
fixed-effect and random-effect meta-analysis showed
that the latter were consistently more conservative
across all traits (Supplementary Figure 11, available
as Supplementary data at IJE online).
We observed marked heterogeneity among combined
SMDs for all traits (Figure 3). However, based on both
stratified and meta-regression analyses, we found no
consistent explanation for overall heterogeneity
among studies for each trait, including study-level
Figure 2 Countries contributing data, by region
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factors such as study size, year of study, publication
status or study type (Table 2). Assessment of estimates
stratified by study-level characteristics suggested that
study location may have a modest impact on the mag-
nitude of the association for some traits
(Supplementary Figures 12–19, available as
Supplementary data at IJE online). However, the add-
ition of these variables into meta-regression did not
affect heterogeneity estimates (Table 2
and Supplementary Figures 12–19, available as Supple-
mentary data at IJE online). In addition, heterogeneity
among SMDs in studies could not be explained by con-
founding factors measured at the study level (Table 2).
Visual inspection of forest and Galbraith plots
suggested a variety of outlying studies for several
cardiometabolic traits (Supplementary Figures 3–10
and 20–27, available as Supplementary data at IJE
online), which may also impact on analyses exploring
the determinants of heterogeneity. Sensitivity ana-
lyses examining the impact of extreme outlying stu-
dies on the combined SMDs of the cardiometabolic
traits showed no material change in combined
SMDs for traits found to be associated with HIV in-
fection (Supplementary Tables 4–11, available as Sup-
plementary data at IJE online). However, exclusion of
a single outlying study led to associations, where
there had previously been none, for two additional
cardiometabolic traits—LDL and glucose. Table 3 de-
scribes the range of SMDs obtained for each trait after
sequential exclusion of individual studies.
ART and cardiometabolic traits
In analyses based on up to 3348 HIVþ individuals,
ART exposure was found to be associated with
higher HDL (SMD, 0.39; 95% CI, 0.11 to 0.66) and
LDL levels (SMD, 0.43; 95% CI, 0.14 to 0.72) and
lower HbA1c levels (SMD, 0.34; 95% CI, 0.62 to
0.06) (Figure 4). By contrast, no appreciable
differences were observed for BMI (SMD, 0.12; 95%
CI, 0.11 to 0.34) or TGs (SMD, 0.09; 95% CI, 0.04
to 0.21) between ART users and non-users (Figure 4).
Based on data from up to 2087 participants, we did
not detect any association between ART use and SBP,
DBP or fasting blood glucose (Figure 4). Individual
study SMDs and combined estimates for each cardio-
metabolic trait are presented in Supplementary
Figures 28–35, available as Supplementary data at
IJE online. Estimates from random-effects meta-ana-
lysis were consistently more conservative than those
from fixed-effects meta-analysis for all traits
(Supplementary Figure 36, available as
Supplementary data at IJE online).
Similar to analyses between HIV infection and car-
diometabolic traits, we found marked heterogeneity
among SMDs for all traits (Figure 4). However, stra-
tified and meta-regression analyses did not consist-
ently explain heterogeneity in estimates among
studies (Table 2 and Supplementary Figures 37–44,
available as Supplementary data at IJE online).
Again, assessment of potential study-level effect-
modification factors through meta-regression did not
show clear evidence to suggest that these explained
heterogeneity among studies (Table 2 and Supple-
mentary Figures 37–44, available as Supplementary
data at IJE online).
Based on visual assessments of forest and Galbraith
plots, we found evidence of several outlying studies
assessing the association between ART use and cardi-
ometabolic traits (Supplementary Figures 28–35 and
45–52, available as Supplementary data at IJE online).
Nevertheless, none of the combined SMDs that were
associated with ART use materially changed during
sequential exclusion (Table 3). We did, however, ob-
serve a change in SMD estimates for DBP on exclu-
sion of one study, and for TGs on exclusion of one
study, leading to associations between ART use and
Table 1 Characteristics of included studies, by region
Number
of studies
per region
Number
of previously
published
participants
Number of
unpublished
participants
Total
number of
participants
Number of participants
by exposure group
HIVþ HIV ARTþ ART
East Africa 23 9487 5586 15 073 6064 9009 1120 2674
West and Central Africa 17 7878 0 7878 4422 3456 622 648
Southern Africa 12 5754 1050 6804 2271 4533 600 906
Total 52 23 119 6636 29 755 12 757 16 998 4342 4228
Number of participants with data on each risk factor
TG HDL LDL BMI SBP DBP Fasting glucose HbA1c
East Africa 7791 7772 7777 14 315 6147 6146 459 5551
West and Central Africa 1627 1627 1627 6623 726 726 335 208
Southern Africa 6031 5581 5529 6602 6336 6339 4286 305
Total 15 449 14 980 14 933 27 540 13 209 13 211 5080 6064
BMI, body mass index; TGs, triglycerides; LDL, low-density lipoprotein cholesterol; HDL, high-density lipoprotein cholesterol; SBP,
systolic blood pressure; DBP, diastolic blood pressure; HbA1c, glycated haemoglobin; ART, antiretroviral therapy.
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these cardiometabolic traits where there had previ-
ously been none. Individual combined SMDs for
each sensitivity analysis are presented in Supplemen-
tary Tables 12–19, available as Supplementary data at
IJE online.
Individual participant data analysis
To explore the potential effects of confounding on as-
sociation estimates, we carried out individual partici-
pant data analysis in a subset of data adjusting for
all potential confounders. Analysis of individual partici-
pant data from 5586 individuals in the GPC study,
Uganda, was broadly consistent with summary esti-
mates from meta-analysis for associations between
HIV, ART and cardiometabolic traits. HIV infection
was associated with higher TGs (SMD, 0.28; 95% CI,
0.17 to 0.39) and lower LDL (SMD, 0.18, 95% CI,
0.29 to 0.07), HDL (SMD, 0.26; 95% CI, 0.37
to 0.14) and SBP (SMD, 0.17; 95% CI, 0.26 to
0.08) when adjusted for age, sex, BMI, ART exposure,
education level and smoking status and clustered by
village and household status (Figure 5). In addition,
we found a weak association between HIV infection
and higher HbA1c levels (SMD, 0.14; 95% CI, 0.04 to
0.24) in the fully adjusted model (Figure 5). Comparing
ART exposed and unexposed HIV-infected individuals,
we found associations between ART use and higher
LDL (SMD, 0.18; 95% CI, 0.02 to 0.34), HDL cholesterol
levels (SMD, 0.67; 95% CI, 0.47 to 0.87), lower TGs
(SMD, 0.21; 95% CI, 0.38 to 0.03) and HbA1c
levels (SMD, 0.23; 95% CI, 0.37 to 0.08). In both
analyses, fully adjusted estimates showed stronger as-
sociations than unadjusted estimates, suggesting that
in this situation unadjusted estimates are more conser-
vative than fully adjusted estimates. Sub-analyses com-
paring associations across all three subgroups (HIV,
HIVþ/ART and HIVþ/ARTþ) in the GPC population
are presented in Supplementary Table 3, available as
Supplementary data at IJE online.
Discussion
In this meta-analysis of data from up to 29 755 indi-
viduals in SSA, HIV infection was found to be asso-
ciated with lower BMI, lower SBP, lower DBP, higher
TGs and lower HDL levels. Among HIV-infected indi-
viduals, ART treatment was associated with higher
LDL and HDL, as well as lower HbA1c levels.
BMI
TG
LDL
HDL
SBP
DBP
Glucose
HbA1c
factor
Risk
15928
9916
9657
9699
9617
9617
2735
5352
participants
HIV-
93.4
91.6
91.1
96.1
84.1
87.6
98.5
82.5
(%)
I-squared
-0.32 (-0.45, -0.18)
0.26 (0.08, 0.44)
-0.16 (-0.34, 0.03)
-0.59 (-0.86, -0.31)
-0.40 (-0.55, -0.25)
-0.34 (-0.51, -0.17)
0.35 (-0.35, 1.06)
-0.07 (-0.39, 0.25)
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Figure 3 Summary of overall estimates from random-effects meta-analyses of associations between HIV and individual
cardiometabolic risk factors. SMD, standardized mean difference; CI, confidence interval; BMI, body mass index; TGs,
triglycerides; LDL, low-density lipoprotein cholesterol; HDL, high-density lipoprotein cholesterol; SBP, systolic blood pres-
sure; DBP, diastolic blood pressure; HbA1c, glycated haemoglobin
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Heterogeneity among study estimates did not appear
to be consistently explained by study-level factors,
including potential confounders. These findings are
broadly consistent with published results from popu-
lations of European descent.78,79 In a region with ap-
proximately 22.9 million cases of HIV and many
millions of people on ART,1 it will be important to
clarify these findings to reliably assess the need for
monitoring and managing cardiometabolic risk in SSA
populations.
Whereas several studies have documented lipid and
glucose abnormalities in HIV-infected individuals and
those treated with ART, the pathophysiology of these
differences remains unclear. Higher levels of TGs in
HIV-infected individuals have been attributed to
higher concentrations of very-low-density lipoprotein
cholesterol (VLDL) in plasma, and enrichment of LDL
and HDL particles for TGs.79 TG clearance has been
shown to be decreased in AIDS and HIVþ individuals,
and elevated cytokine levels, such as IFN-alpha,
might be involved in slowed clearance.80 It has been
suggested that these changes may be due, in part, to
the inflammatory effects of the viral infection.79
Several mechanisms have been outlined for the asso-
ciation between ART and dyslipidaemia, including
reduced synthesis of cis-9-retinoic acid, leading to
dysregulation of adipocyte differentiation and apop-
tosis, increased hepatic TG synthesis,81 increase in
dense LDL particles, a shift towards TG-rich VLDL
and increase in apolipoprotein C-III- and apolipopro-
tein E-containing particles. However, mechanisms are
thought to be different for the various classes of ART
drugs.79
Associations between HIV, ART and blood lipids
observed in this meta-analysis are consistent with
studies from Europe and North America, which
show that HIV infection in ART-naive individuals is
associated with hypertriglyceridaemia and lower HDL
and LDL levels78,79 whereas ART use is associated
with higher HDL and LDL levels.78,82–84 Both the
Table 3 Sensitivity analysis of the change in combined standardized mean difference estimates after sequential exclusion
of single studies
Combined estimate obtained
before sequential exclusion
Range of SMDs
obtained from
sequential exclusion
of individual studies
Instance in which exclusion
of a single study produced a
change in interpretation
SMD (95% CI) I2 SMD (95% CI) I2
HIV associations
BMI 0.32 (0.45 to 0.18) 93.4% 0.34 to 0.26 –
TGs 0.26 (0.08 to 0.44) 91.6% 0.16 to 0.30 –
LDL 0.16 (0.34 to 0.03) 91.1% 0.27 to 0.11 Association observed after study exclusion30
0.27 (0.39 to 0.14) 79.4%
HDL 0.59 (0.86 to 0.31) 96.1% 0.65 to 0.44 –
SBP 0.40 (0.55 to 0.25) 84.1% 0.44 to 0.37 –
DBP 0.34 (0.51 to 0.17) 87.6% 0.39 to 0.26 –
Glucose 0.35 (0.35 to 1.06) 98.5% 0.14 to 0.50 Association observed after study exclusion51
0.14 (0.26 to 0.02) 43.0%
HbA1c 0.07 (0.39 to 0.25) 82.5% 0.16 to 0.04 –
ART associations
BMI 0.12 (0.11 to 0.34) 91.0% 0.02 to 0.15 –
TGs 0.09 (0.04 to 0.21) 65.7% 0.05 to 0.12 Association observed after study exclusion74
0.12 (0.00 to 0.24) 59.1%
LDL 0.43 (0.14 to 0.72) 93.4% 0.34 to 0.53 –
HDL 0.39 (0.11 to 0.66) 92.9% 0.31 to 0.49 –
SBP 0.05 (0.19 to 0.28) 83.4% 0.3 to 0.16 –
DBP 0.06 (0.10 to 0.22) 64.6% 0.00 to 0.16 Association observed after study exclusion30
0.16 (0.06 to 0.26) 8.8%
Glucose 0.23 (0.61 to 0.16) 90.4% 0.34 to 0.04 –
HbA1c 0.34 (0.62 to 0.6) 56.9% 0.23 to 0.52 –
–, combined SMD did not change statistical significance due to the sequential exclusion of any single study; CI, confidence interval;
BMI, body mass index; TGs, triglycerides; LDL, low-density lipoprotein cholesterol; HDL, high-density lipoprotein cholesterol; SBP,
systolic blood pressure; DBP, diastolic blood pressure; HbA1c, glycated haemoglobin; ART, antiretroviral therapy.
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magnitude and the direction of HIV and ART associ-
ations with HDL and LDL are consistent with reported
estimates. We did not find an association between
ART and TGs in this study, which is inconsistent
with a meta-analysis of randomized clinical trials re-
porting a positive association between first-line ART
and TGs, with stronger associations observed in pro-
tease inhibitor-treated patients.82 Furthermore, results
for the association between ART exposure and TG
were inconsistent between meta-analysis of summary
data and individual participant data from the GPC.
These inconsistencies are likely to be due to different
treatment regimens across studies and infrequent use
of protease inhibitors in comparison with nucleoside
reverse transcriptase inhibitors and non-nucleoside
reverse transcriptase inhibitors (NNRTI) in SSA.85–87
Indeed, regimens based on nevirapine (an NNRTI
drug) are the most commonly used in the GPC
HIVþ patient population, which may explain the in-
verse association between ART exposure and TG in
the individual-level analysis, as previously noted.87
Similarly, the inverse association between HIV infec-
tion and BMI in SSA populations is consistent with
previously published findings in populations of
European descent.88 Advanced stages of HIV have
been consistently associated with a rapid decrease in
BMI.89 There is also clear evidence supporting the role
of HIV infection and ART use in the pathogenesis of
lipodystrophy, and the effects these changes in body-
fat redistribution may have on cardiometabolic
traits.51,79–90 However, in our individual-level dataset
neither HIV nor ART is associated with differences in
BMI. Thus, it is unclear what effect BMI has on the
relationship among HIV, ART and cardiometabolic
traits in these populations.
Our analyses found that individuals infected with
HIV in SSA had lower DBP and SBP than uninfected
controls, regardless of ART status. Previous studies
assessing the associations between HIV, ART and
blood pressure have been inconsistent, with some stu-
dies suggesting increased risk of hypertension with
ART,91 some reporting no association with HIV or
ART92,93 and others supporting the findings of this
meta-analysis.94 There is no clear biological mechan-
ism that might account for such associations. One
explanation for our findings may be residual con-
founding in our meta-analysis of study-level data.
Indeed, both BMI and blood pressure were inversely
associated with HIV in our data. However, individual
participant analysis in a subset of data showed the
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association between SBP and HIV infection was
robust to adjustment for potential confounders.
Nevertheless, we cannot exclude residual or unknown
confounding as a possible explanation. Equally, al-
though the lack of association between ART and
blood pressure seen in our analysis supports previ-
ously published results,92,95only a small number of
studies reported blood pressure measurements in
both ARTþ and ART- populations, suggesting these
results require further evaluation.
We did not find an association between HIV infec-
tion, ART use and fasting blood glucose levels.
Whereas this finding is consistent with findings
from several large prospective11,96,97 and cross-sec-
tional studies,98 it does not agree with findings from
some large studies in populations of European descent
that have reported associations between HIV infec-
tion, ART use and increased risk of T2D.10–12,99 One
explanation for this may be the relative scarcity of
relevant studies and the relatively small sample sizes
in our data. Furthermore, the direction and
magnitude of the association may differ in African
populations, as suggested previously in analyses
among African-American women in the Women’s
Interagency HIV study.100 Although adjusted esti-
mates from individual participant analyses suggested
inverse associations between HIV and HbA1c, and
positive associations between ART exposure and
HbA1c, it must be noted that haemoglobin levels
and red cell turnover may be altered by HIV infection
and ART exposure, and HbA1c in these individuals
may not be accurately representative of glycaemic
status.101 Specific, large-scale prospective studies in
sub-Saharan Africa are needed to more reliably
assess these associations.
Differences in cardiometabolic traits among HIV,
HIVþ and ART users and non-users may have import-
ant implications for the management of people in-
fected with HIV. Antiretroviral therapy has greatly
improved the survival of HIV-infected patients living
today; however, the mortality rates in HIV patients
are still higher than in the general population and
the proportion of deaths due to non-HIV-related
causes including cardiometabolic diseases, is increas-
ing.102,103 Dyslipidaemia is common among patients
with HIV and has been shown to be associated with
increased cardiovascular disease risk in this patient
population.80,104 Furthermore, there is evidence to
support an independent role of HIV infection on car-
diometabolic disease risk, after accounting for trad-
itional risk factors and exposure to ART.79 In the
Data Collection on Adverse Events of Anti-HIV
Drugs (DAD) cohort of 23 468 HIV-infected patients,
higher total serum cholesterol and TGs and presence
of diabetes were associated with an increased risk of
myocardial infarction.14 Differences in average levels
of cardiometabolic traits among subpopulations might
also result in important differences in cardiovascular
disease risk. For example, a 1-SD increase in LDL and
HDL each were associated with a relative risk of 1.4
and 0.6, respectively, for coronary heart disease in the
Atherosclerosis Risk in Communities Study (ARIC)
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Figure 5 Participant-level data on the associations of HIV and ART with cardiometabolic traits in the General Population
Cohort,54 adjusted for different amounts of individual-level confounding. Full adjustment includes adjustment for data
clustering, ART exposure (when comparing HIVþ and HIV subgroups), age, sex, BMI, education level and smoking status.
SMD, standardized mean difference; CI, confidence interval; BMI, body mass index; TGs, triglycerides; LDL, low-density
lipoprotein cholesterol; HDL, high-density lipoprotein cholesterol; SBP, systolic blood pressure; DBP, diastolic blood pres-
sure; HbA1c, glycated haemoglobin; ART, antiretroviral therapy
ASSOCIATION OF HIV AND ART WITH CARDIOMETABOLIC TRAITS IN SUB-SAHARAN AFRICA 1765
examining 12 336 individuals, indicating that a
change of 0.6 SD in HDL and/or 0.4 SD in LDL
observed in our meta-analysis may have important
implications for modifying cardiovascular risk in
these groups.105
Findings from this meta-analysis should be inter-
preted within the context of its strengths and limita-
tions. One of the strengths of the study is the large
sample of individuals examined from different stu-
dies. We used a comprehensive and systematic
search strategy examining two separate journal data-
bases and contacted authors of studies for information
on unpublished data and grey literature. Although the
restriction of our search to only PubMed and EMBASE
could be seen as a limitation, we feel that the combin-
ation of cited reference list searches and direct author
contact helps ameliorate this concern. Furthermore,
study eligibility was rigorously assessed by two inde-
pendent reviewers, making assessment bias unlikely.
However, we acknowledge that restricting this system-
atic review to English language articles may not be
representative of the non-English literature. We were
unable to correct for confounders at the individual
level for all studies. Although none of the study-level
characteristics and indices for study design substan-
tially explained the heterogeneity among estimates
from studies, we cannot rule out confounding at the
individual level. Meta-regression approaches also have
limited statistical power with sparse data. However, we
were able to evaluate the potential effects of residual
confounding with individual participant data analysis
in a large cohort study, comprising nearly one-fifth of
the overall data. Individual-level adjustment for con-
founders in a subset of data showed that SMDs are
likely to be under-estimated (more conservative) in
unadjusted analysis across most traits, suggesting
that association estimates from summary data are un-
likely to be overestimated. Unexplained heterogeneity
could be attributed to one or more of several factors,
including differences in study design and objective, dif-
ferential confounding in each study due to age, sex,
participant CD4 count or WHO stage, type and dur-
ation of ART treatment, co-infections or differences
in data collection and laboratory assays. However,
our findings are broadly consistent with published
findings in populations of European descent,78,79,106
as well as studies using individual-level data to
assess these associations.35,57,107
An additional limitation of this study is the inability
to delineate associations by ART drug class, due to
insufficient data. Such analyses would be invaluable
in understanding these associations, and their results
would likely be of direct clinical relevance.
Nevertheless, despite a lack of specific information
on drug class, we identified associations between gen-
eral ART use and differences in several cardiometa-
bolic traits. It is likely that combining the impact of
several different drugs in a single analysis would
underestimate the individual effects of each drug.
Based on data presented here, the cardiometabolic
consequences of HIV infection and ART exposure in
SSA may be important. With a rapid increase in ART
use over the past decade,1 an increasing number of
SSA individuals are receiving treatment.3 As people
live longer with HIV, it will become increasingly im-
portant to monitor their risk of other diseases. The
HIV Medicine Association of the Infectious Disease
Society of America, and the Adult AIDS Clinical
Trials Group, published guidelines specifically for
management of dyslipidaemia in HIV-infected indi-
viduals in 2003.15 Following this, the European
AIDS Clinical Society (EACS) also published guide-
lines on the prevention and management of metabolic
disease in HIV infection in 2008.108 Both these sets of
guidelines have been based largely on evidence from
studies in European populations and the impact of
HIV infection and ART use on metabolic traits, and
the utility of early screening and treatment in popu-
lations from SSA remains largely unknown. There is
evidence to suggest that baseline metabolic profiles20
and associations between HIV and ART and metabolic
risk factors may be different in different ethnic popu-
lations,109 with HIV-infected African-Americans being
at higher risk of acute MI in comparison with indi-
viduals of European descent.18,19,109,110 This empha-
sises the need to examine these factors in SSA,
where the burden of HIV infection is the greatest.
Our results suggest that, with further evaluation,
there may be a need to monitor cardiometabolic
traits in HIV-infected individuals in SSA. One mech-
anism to achieve this, in the context of resource-poor
settings, is to integrate care of chronic HIV with that
of cardiometabolic diseases.111 Such routine monitor-
ing has the potential to improve the management of
cardiovascular disease among HIV-infected and ART-
exposed individuals.111
The results of this meta-analysis suggest that HIV
infection and ART treatment are both associated with
differences in cardiometabolic traits compared with
HIV-uninfected or ART-naı¨ve patients in SSA.
Individual-level associations from a subset of 5586 in-
dividuals, adjusted for several major cardiometabolic
confounders, were generally consistent with study-
level summary results, suggesting that the results
from meta-analysis are likely to be robust to major
confounding. To our knowledge, this is the first com-
prehensive study examining the association between
HIV and cardiometabolic traits by a meta-analysis of
published and unpublished data from SSA. These
findings may have important implications for man-
agement of HIV in SSA, given the increasing use of
ART and improved life expectancy among HIV-in-
fected individuals in this region, and could provide
a framework for further research aimed towards the
development of specific guidelines for assessment and
management of cardiometabolic risk in HIV-infected
individuals in the region. More comprehensive ana-
lyses, including the collection of prospective
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observational data, and a pooled analysis of individ-
ual-level cross-sectional data from the region are
needed to clarify these findings and reliably assess
the need for monitoring and managing cardiometa-
bolic risk in populations in SSA.
Supplementary Data
Supplementary data are available at IJE online.
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KEY MESSAGES
 Sub-Saharan Africa has the highest burden of HIV in the world and a rising prevalence of cardio-
metabolic disease.
 We assessed the associations among HIV, ART and cardiometabolic traits in 29 755 individuals
from 49 published and 3 unpublished studies, including an individual-level analysis of 5586
participants.
 Our results are broadly consistent with results from populations of European descent, and suggest
differences in cardiometabolic traits between HIV-infected and uninfected individuals in sub-Saharan
Africa, which might be modified by ART use.
 These findings provide a framework for further research aimed towards the development of specific
guidelines for the assessment and management of cardiometabolic risk in HIV-infected individuals in
the region.
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